2Kivikko M, Lehtonen L, et al. Sustained hemodynamic effects of intravenous levosimendan [ J ]. Circulation, 2003, 107, 81 - 86.
3Slawsky MT, Colucci WS, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure[ J]. Circulation, 2000, 102, 2222 - 2227.
4Moiseyew VS, Poder P, et al. RUSSLAN study investigations. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study( RUSSLAN )[Jl. EurHeart J, 2002. 23, 1422 -1432.
5Giustaina A, Lorusso R, et al. Impaired spontaneous growth hormone secrection in severe dilated cardiomyopathy [ J ]. Am Heart J,1996, 131 : 620 -622.
6Fazio S, Sabatini D, et al. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy[ Jl. N Engl J Med, 1996,334:809 - 814.
2[1]Mornuzi P,Doria E,Agostoni PG,et al.Usefulness of 1-thyroxine to improve cardiac and exercise performance in idiopathic dilated cardiomyopathy.Am j Cardiol.1994,73:374.
3[2]Hamilton MA,Stevenson LW,Luu M,et al.Altered thyroid hormone matabolism in advanced heart failure.J Am Coll Cardial.1990,16:91.
4[3]Ojarnax K,Balkman C,Kiein I.Acute effects of triodothyronine on arterial smooth muscle cells.Am Thorac Surg.1993,56:561.
